Citations

Mayo Clinic

Clear

1292 citation(s) found for "Wu, Jeremy".

Evidence-Based Guidelines for Management of Diabetic Macular Edema
Bakri, Sophie J. , Regillo, Carl D. , Wolfe, Jeremy D. , Flynn, Harry W. , Wykoff, Charles C.

Journal of VitreoRetinal Diseases | April 24, 2019 | Volume: 3 | Issue: 3 | Pages: 145-152

10.1177/2474126419834711 Get It

Purpose: The purpose of this article is to provide a data-driven set of best practices to consider in the management of diabetic macular edema (DME). Methods: The current discussion and recommendations represent the authors’ interpretations of data from selected references based on perceived relevance and study design. Results: DME is a common cause of visual impairment globally. The underlying progressive retinal microvascular damage is associated with upregulation of VEGF and a multitude of other inflammatory pathways. Three clinically relevant subcategories of DME can be identified: central-involved DME (CIDME) with preserved visual acuity, CIDME with associated visual loss, and non-CIDME. Management approaches may include observation, laser photocoagulation, intravitreal pharmacotherapy with anti-VEGF agents or corticosteroids, or a combination of these, and may vary depending on the specific type of DME and associated severity of diabetic retinopathy. Additional factors to consider in the management of patients with DME include the appropriate use of imaging and recognition of the chronic nature of the underlying disease process in many eyes. Conclusions: DME management is complex. Intravitreal pharmacotherapies are the current cornerstone of treatment for CIDME and appear poised to remain so for the foreseeable future.
Evaluation of bone fracture healing in children using acoustic radiation force: Initial in vivo results
Ghavami, Siavash , Gregory, Adriana , Webb, Jeremy, Denis, Max , Milbrandt, Todd A. , Kumar, Viksit , Larson, A. Noelle , Fatemi, Mostafa , Alizad, Azra

The Journal of the Acoustical Society of America | April 24, 2019 | Volume: 145 | Issue: 3_Supplement | Pages: 1893-1893

10.1121/1.5101860 Get It

Vibrational characteristics of the bone are directly dependent on bone’s physical properties. In this paper, a vibrational method for bone evaluation is introduced. We propose a new type of quantitative vibro-acoustic method based on acoustic radiation force of ultrasound for bone characterization in patients with fracture. In this method, we excite the clavicle and ulna by an ultrasound radiation force (URF) pulse. The URF pulse induces vibrations in the bone, resulting in an acoustic wave that is measured by a hydrophone placed on the skin. The resulting acoustic signals were used for wave velocity estimation based on cross-correlation technique. To further separate different vibration characteristics, we adopt a variational mode decomposition (VMD) technique to decompose the received signal into an ensemble of band-limited intrinsic mode functions, which allows analyzing the acoustic signals in terms of their constitutive components. We conducted a prospective study that included a total of 15 patients, 12 with clavicle fractures and 3 with ulna fractures. The contralateral intact bones were used as control. Statistical analysis demonstrated that fracture bones can be differentiated from intact bone with a detection probability of 80%. Also, we introduce a “healing factor” that quantifies the progress of healing in clavicle bones. Statistical analysis showed that healing factor can track the progress of healing in clavicle in 80% of fractures.
Patterns of AKT, mTOR, ERK, and STAT3 pathway activation in MGUS, smoldering multiple myeloma, and multiple myeloma.
Larsen, Jeremy T. , Wellik, Linda, Kimlinger, Teresa K. , Kumar, Shaji , Ramakrishnan, Vijay , Rajkumar, S. Vincent

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8589-8589

10.1200/jco.2015.33.15_suppl.8589 Get It

Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
Chanan‐Khan, Asher , Agarwal, Amit , Lebovic, Daniel, Darden, David E., Morris, Lura, Munasinghe, Wijith, Zhu, Ming , Enschede, Sari H., Humerickhouse, Rod, Touzeau, Cyrille , Roberts, Andrew W. , Facon, Thierry T.F. , Moreau, Philippe , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8580-8580

10.1200/jco.2015.33.15_suppl.8580 Get It

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
Kumar, Shaji , Vij, Ravi , Alzate, Stefanie, Morris, Lura, Dunbar, Martin, Zhu, Ming , Enschede, Sari H., Humerickhouse, Rod, Kaufman, Jonathan L. , Mıkhael, Joseph , Facon, Thierry T.F. , Moreau, Philippe , Amiot, Martine , Ross, Jeremy A. , Agarwal, Suresh K, Leverson, Joel D. , Touzeau, Cyrille

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8576-8576

10.1200/jco.2015.33.15_suppl.8576 Get It

Influence of Age, Sex, and Body Mass Index on the Thickness of the Gluteal Subcutaneous Fat: Implications for Safe Buttock Augmentation Procedures
Frank, Konstantin , Kaye, Kai , Lorenc, Paul, Schenck, Thilo L., Lachman, Nirusha , Durán-Vega, Héctor César , Cotofana, Sebastian, Gotkin, Robert H., Kaye, Kai O, Lorenc, Paul Z, Green, Jeremy B, Duran-Vega, Héctor, Casabona, Gabriela , Gotkin, Robert H. , Green, Jeremy B. , Cotofana, Sebastian

Plastic & Reconstructive Surgery | April 18, 2019 | Volume: 144 | Issue: 1 | Pages: 83-92

10.1097/prs.0000000000005707 | PMID 31246807 Get It

Background: The deep intramuscular approach during buttock augmentation with fat grafting has been associated with a significantly increased risk for pulmonary fat embolism. This study was designed to provide guidance for injection into the subcutaneous fat. Methods: The authors investigated 150 Caucasian individuals with an equal distribution of men and women (n = 75 each) and a balanced distribution of age (n = 30 per decade: 20 to 29, 30 to 39, 40 to 49, 50 to 59, and 60 to 69 years) and body mass index (n = 50 per group: ≤24.9 kg/m2, between 25.0 and 29.9kg/m2, and ≥30 kg/m2). Ultrasound-based measurements were conducted of the thickness of the total, superficial, and deep gluteal fatty layers. Results: An increase in body mass index of 1.0 kg/m2 corresponded to an increase of 3 mm of the total gluteal subcutaneous fat of men and a 4-mm increase of the total gluteal subcutaneous fat in women. With increasing age, the thickness of the deep fatty layer increased, whereas with increasing body mass index the thickness of the superficial layer primarily increased. Formulas were generated to estimate the total thickness of the gluteal subcutaneous fatty layer for men [total thickness (in millimeters) = −33.56 + (age × 0.078) + (body mass index × 3.042)] and women [total thickness (in millimeters) = −56.997 + (age × 0.1) + (body mass index × 3.86)]. Conclusions: Knowing the total thickness of the gluteal subcutaneous fat (i.e., the safe space) allows surgeons to estimate their operating range for cannula motion even if no ultrasound machine is available during buttock augmentation with fat grafting. This can increase safety, potentially reducing the number of adverse events.
Validity evidence for Quality Improvement Knowledge Application Tool Revised (QIKAT-R) scores: consequences of rater number and type using neurology cases
Kassardjian, Charles D. , Park, Yoon Soo , Braksick, Sherri A. , Cutsforth‐Gregory, Jeremy K. , Robertson, Carrie, Hunderfund, Andrea N. Leep , Robertson, Carrie E. , Cutsforth-Gregory, Jeremy, Young, Nathan, Leep Hunderfund, Andrea , Park, Yoon Soo , Robertson, Carrie E , Robertson, Carrie, Young, Nathan P.

BMJ Quality & Safety | April 17, 2019 | Volume: 28 | Issue: 11 | Pages: 925-933

10.1136/bmjqs-2018-008689 | PMID 30996038 Get It

Objectives To develop neurology scenarios for use with the Quality Improvement Knowledge Application Tool Revised (QIKAT-R), gather and evaluate validity evidence, and project the impact of scenario number, rater number and rater type on score reliability. Methods Six neurological case scenarios were developed. Residents were randomly assigned three scenarios before and after a quality improvement (QI) course in 2015 and 2016. For each scenario, residents crafted an aim statement, selected a measure and proposed a change to address a quality gap. Responses were scored by six faculty raters (two with and four without QI expertise) using the QIKAT-R. Validity evidence from content, response process, internal structure, relations to other variables and consequences was collected. A generalisability (G) study examined sources of score variability, and decision analyses estimated projected reliability for different numbers of raters and scenarios and raters with and without QI expertise. Results Raters scored 163 responses from 28 residents. The mean QIKAT-R score was 5.69 (SD 1.06). G-coefficient and Phi-coefficient were 0.65 and 0.60, respectively. Interrater reliability was fair for raters without QI expertise (intraclass correlation = 0.53, 95% CI 0.30 to 0.72) and acceptable for raters with QI expertise (intraclass correlation = 0.66, 95% CI 0.02 to 0.88). Postcourse scores were significantly higher than precourse scores (6.05, SD 1.48 vs 5.22, SD 1.5; p < 0.001). Sufficient reliability for formative assessment (G-coefficient > 0.60) could be achieved by three raters scoring six scenarios or two raters scoring eight scenarios, regardless of rater QI expertise. Conclusions Validity evidence was sufficient to support the use of the QIKAT-R with multiple scenarios and raters to assess resident QI knowledge application for formative or low-stakes summative purposes. The results provide practical information for educators to guide implementation decisions.
White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
Alber, Jessica , Alladi, Suvarna , Barton, David A., Bell, Joanne M., Berman, Sara E., Biessels, Geert Jan , Bos, Isabelle , Bowman, Gene L. , Brai, Emanuele , Callahan, Brandy L. , Corriveau, Roderick A. , Fossati, Silvia , Gottesman, Rebecca F. , Gustafson, Deborah , Hachinski, Vladimir , Hayden, Kathleen M. , Helman, Alex M., Hughes, Timothy M. , Isaacs, Jeremy D. , Jefferson, Angela L. , Kern, Silke , Kwon, Jay C., Lee, Athene , Lockhart, Samuel N. , Murray, Anne M. , Osborn, Katie E. , Price, Brittani R. , Rhodius‐Meester, Hanneke , Rondeau, Jacqueline A., Rosen, Allyson , Scholtzova, Henrieta , Shaaban, C. Elizabeth , Silva, Nárlon Cássio Boa Sorte , Snyder, Heather M. , Swardfager, Walter , Troen, Aron M. , Vemuri, Prashanthi , Wallin, Anders , Wellington, Cheryl L. , Xie, Sharon X. , Hainsworth, Atticus H. , Vemuri, Prashanthi , Gottesman, Rebecca F , Hainsworth, Atticus H , Bae, Hee‐Joon , Beckett, Laurel , Biessels, Geert Jan , Black, Sandra E. , Brickman, Adam M. , Johnson, Sterling C. , Kapasi, Alifiya , Kukolja, Juraj , Power, Melinda C. , Rosene, Douglas L , Schneider, Julie A. , Veluw, Susanne J. van , Wilcock, Donna M.

Alzheimer's & Dementia: Translational Research & Clinical Interventions | April 8, 2019 | Volume: 5 | Issue: 1 | Pages: 107-117

10.1016/j.trci.2019.02.001 | PMID 31011621 Get It

Abstract White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small vessel disease, WMHs are associated with increased likelihood of cognitive impairment and dementia (including Alzheimer's disease [AD]). WMHs are also seen in cognitively healthy people. In this collaboration of academic, clinical, and pharmaceutical industry perspectives, we identify outstanding questions about WMHs and their relation to cognition, dementia, and AD. What molecular and cellular changes underlie WMHs? What are the neuropathological correlates of WMHs? To what extent are demyelination and inflammation present? Is it helpful to subdivide into periventricular and subcortical WMHs? What do WMHs signify in people diagnosed with AD? What are the risk factors for developing WMHs? What preventive and therapeutic strategies target WMHs? Answering these questions will improve prevention and treatment of WMHs and dementia.
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Bartlett, Nancy L. , Wilson, Wyndham H. , Pederson, Levi , Polley, Mei‐Yin C. , Pitcher, Brandelyn N., Cheson, Bruce D. , Friedberg, Jonathan W. , Staudt, Louis M. , Wagner‐Johnston, Nina D. , Blum, Kristie A. , Reddy, Nishitha , Chang, Julie , Chadburn, Amy , Mathew, Susan , Fisher, Richard I., Richards, Kristy L. , Leonard, John P. , Bartlett, Nancy L , Jung, Sin‐Ho , Hsi, Eric D. , Maurer, Matthew J. , Kahl, Brad S. , Abramson, Jeremy S. , Winter, Jane N. , Gopal, Ajay K. , Schöder, Heiko , Zelenetz, Andrew D.

Journal of Clinical Oncology | April 2, 2019 | Volume: 37 | Issue: 21 | Pages: 1790-1799

10.1200/jco.18.01994 | PMID 30939090 Get It

PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma. PATIENTS AND METHODS Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall survival (OS), and safety. RESULTS Between 2005 and 2013, 524 patients were registered; 491 eligible patients were included in the final analysis. Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5. At a median follow-up of 5 years, PFS was not statistically different between the arms (hazard ratio, 0.93; 95% CI, 0.68 to 1.27; P = .65), with a 2-year PFS rate of 78.9% (95% CI, 73.8% to 84.2%) for DA-EPOCH-R and 75.5% (95% CI, 70.2% to 81.1%) for R-CHOP. OS was not different (hazard ratio, 1.09; 95% CI, 0.75 to 1.59; P = .64), with a 2-year OS rate of 86.5% (95% CI, 82.3% to 91%) for DA-EPOCH-R and 85.7% (95% CI, 81.4% to 90.2%) for R-CHOP. Grade 3 and 4 adverse events were more common ( P < .001) in the DA-EPOCH-R arm than the R-CHOP arm, including infection (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucositis (8.4% v 2.1%, respectively), and neuropathy (18.6% v 3.3%, respectively). Five treatment-related deaths (2.1%) occurred in each arm. CONCLUSION In the 50303 study population, the more intensive, infusional DA-EPOCH-R was more toxic and did not improve PFS or OS compared with R-CHOP. The more favorable results with R-CHOP compared with historical controls suggest a potential patient selection bias and may preclude generalizability of results to specific risk subgroups.
Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI)
Kiely, David G. , Levin, David L. , Ivy, D. Dunbar , Bwika, Jumaa, Lordan, Jim , Mazurek, Jeremy A. , Moledina, Shahin , Olschewski, Horst , Peacock, Andrew J. , Puri, G. D., Rahaghi, Farbod N. , Schäfer, Michal , Screaton, Nicholas, Noordegraaf, Anton Vonk , Vandepool, Rebecca, Wort, Stephen J. , Zhao, Lan , Wild, Jim M. , Vogel‐Claussen, Jens , Swift, Andrew J. , Vanderpool, Rebecca , Levin, David, Olschewski, Horst , Vonk Noordegraaf, Anton , Vanderpool, Rebecca R , Wild, Jim M , Hassoun, Paul M. , Jone, Pei-Ni , Kawut, Steven M. , Lungu, Angela , Schiebler, Mark , Tawhai, Merryn Howatson , Beek, Edwin J.R. van , Kiely, David , Vogel-Claussen, Jens

Pulmonary Circulation | March 18, 2019 | Volume: 9 | Issue: 3 | Pages: 1-32

10.1177/2045894019841990 | PMID 30880632 Get It

Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life‐shortening condition. There have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly encountered clinical and radiological scenarios, and imaging and modeling‐based biomarkers. An expert panel was formed including clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55 statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in the diagnosis and assessment of PH and highlight areas requiring further research.